ARQ-234: A High Affinity CD200-Fc Fusion Protein for the Treatment of Atopic Dermatitis

    Rebecca Ashfield, John Sheridan, Jonathan R. Heal … Paul Huxley
    Studysummary This study found that engineered high-affinity soluble CD200R agonists, including ARQ-234, showed superior efficacy in reducing immune responses in various preclinical models of inflammatory conditions, suggesting potential as a therapeutic for atopic dermatitis and other related diseases.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jidonline.org →
    Discuss this study in the Community →